ABSTRACT -The neurochemical and behavioral effects of repeated subdermal administration of methyl parathion (MP) at low doses were investigated. Adult male rats were treated repeatedly with either vehicle or MP subcutaneously (3 mg/kg/day) and observed for the signs of toxicity during the treatment period. The toxic sign, tremor, reached maximum right after 9 th injection in MP-treated rats, and declined thereafter. Animals were sacrificed and brains were taken 1 week or 3 weeks after the daily treatment for measurement of acetylcholinesterase (AChE) 3 H]AF-DX384 binding (6 ~ 38%) in different brain regions, including striatum, hippocampus, frontal cortex, thalamus and midbrain. After 1 week of treatment, the inhibition of AChE in brain regions was from 54 to 74%, whereas receptor densities were only marginally affected in a few regions. The timing of the changes in receptor population correlates well with the changes in behaviors during the repeated MP exposure. Our findings suggest that down-regulation of muscarinic receptors plays a role in the development of tolerance to MP. And, the regulations of muscarinic receptors were different among receptor subtypes and brain regions.
INTRODUCTION
Methyl parathion (MP) is a widely used organophosphorus (OP) insecticide. It is approved only for agricultural use in the United States. Signs of acute toxicity following exposure to OP insecticides are generally attributed to their inhibition of acetylcholinesterase (AChE) in the central and peripheral nervous system, with subsequent accumulation of acetylcholine (ACh) at synaptic terminals (Sauders and Harper, 1994; Brown and Taylor, 1996) , although additional macromolecular targets for some OP compounds may alter the cascade of events following AChE phosphorylation and there by modify this common mechanism (Pope, 1999) . It is generally considered that some degree of AChE inhibition can be tolerated without substantial alteration of cholinergic transmission. With more extensive inhibition (> 50 -60%) of AChE, however, signs of OP poisoning including autonomic dysfunction (e.g., excessive secretion of the airway excretory systems, salivary gland and lacrimal glands), involuntary movement (e.g. tremor, convulsions), muscle fasciculation, and ultimately respiratory depression are elicited (Nostrandt et al., 1997) . Some studies also showed that these neurochemical changes were accompanied by progressive deterioration of cognitive and motor function, during repeated exposures to sublethal doses of diisopropylfluorophosphate (DFP) and disulfoton (Bushnell et al., 1991; Llorens et al., 1993) .
The muscarinic acetylcholine receptors (mAChRs) are the predominant cholinergic receptors in the mammalian brain. In the CNS, there is evidence that muscarinic receptors are involved in motor control, temperature regulation, cardiovascular regulation, and memory (Nathanson, 1987; Felder et al., 2000) . Muscarinic receptor subtypes differ in synaptic and tissue localization, agonist and antagonist affinity, and the second messenger systems associated with them (Caulfield and Birdsall, 1998) . By far the most common and consistent finding on repeated exposure to OP antiAChEs has been a reduction in the number of mAChRs (Schiller, 1979; Costa et al., 1982; Yamada et al., 1983; Churchill et al., 1984a Churchill et al., , 1984b . It has been suggested as the primary mechanism by which animals adapt to or compensate for sustained mAChR activation (Russell and Overstreet, 1987; Hoskins and Ho, 1992) . Yamada et al. (1983) have reported that the decrease in mAChRs is region-and organ-specific. These differences were interpreted that there are variations in the density of cholinergic innervations in tiss u e s . O t h e r s t u d i e s e m p l oy i n g q u a n t i t ive autoradiographic techniques have confirmed the regional specificity of mAChR changes following chronic DFP and soman treatment (Churchill et al., 1984a (Churchill et al., , 1984b . Studies of the effects of OPs on the characteristics and signal transduction of mAChRs also suggested that the subtypes may not be equally sensitive and the mAChR down-regulation by OPs may be more specific for certain subtypes (Smit et al., 1980; Katz and Marquis, 1989) . However, brain regional alteration in receptor subtypes was not studied in detail in MP. Since the regional distribution of muscarinic receptor subtypes in the brain is related to physiological functions, it is important to conduct regional study on the alteration of receptors by OP exposure and its relation to consequent physiological deficits. Different alteration in receptor subtypes for individual OP agent may also explain the phenomena that exposure to various OPs caused similar levels of AChE inhibition and yet induced a different spectrum of toxic signs (Chaudhuri et al., 1993; Liu and Pope, 1998) .
The purpose of the present study is to investigate the effects of repeated MP exposures at low doses on muscarinic receptors population and the consequent behavioral changes. Here, the down-regulation of two pharmacologically defined muscarinic receptor subtypes (M 1 and M 2 ) in different brain regions of the rat by repeated MP exposures are reported. M 1 has high affinity to pirenzepine; whereas M 2 exhibits low affinity to pirenzepine and high affinity to AF-DX116 and related compounds. The muscarinic receptor autoradiographic technique was utilized to detail the distribution of down-regulated receptors in the brain.
MATERIALS AND METHODS

Chemicals
Methyl parathion (purity ≥ 99%) was purchased from Chem Service Inc. (West Chester, PA). Quinuclidinyl benzilate (QNB), L-[benzilic-4, 4'-3 
Animal treatment protocols
Male Sprague-Dawley rats (initial body weight of 175-200 g, Harlan Inc., Indianapolis, IN) were maintained under a 12-hr light/dark cycle in a temperature-controlled environment, with free access to food and water. They were housed for at least one week prior to dosing. Animals were daily treated with either vehicle (peanut oil, 1 ml/kg, s.c.) or MP (3 mg/kg, s.c.) for either one week or 3 weeks. Animals were sacrificed 24 hr after the last injection. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Mississippi Medical Center.
Behavioral analysis
During the period of repeated administrations of MP, the body weight of each rat was recorded daily prior to treatment and the symptom of tremor was assessed for 1 hr every other day 15 min after the injection. Rats were individually placed in observation cages. Tremor was scored individually on each rat for a duration of 5 min, repeated at 30 min intervals. The scoring scale was: 0 = none, 1 = distinct slow tremor of the head; 2 = high frequency vibrations of the head, trunk or limbs; 3 = intense fast tremor (Lim et al., 1987) . The score from each animal was the average value of the two observations.
Preparation of brain slides
After the sacrifice of rats, brains were removed and frozen immediately by immersion in liquid nitrogen. Individual frozen brain was mounted on a tissue holder with embedding medium (Tissue-Tek, Miles Inc.). Horizontal sections, 14 µm thick, were cut on an Tissue-Tek ® Cryo2000 Microtome/Cryostat (Sakura Finetek USA Inc., CA) at −18°C. The stereotaxic coordinates were bregma −4.6 mm / interaural 5.4 mm according to Paxinos and Watson (1998) . The sections were thaw-mounted on microscope slides (Allegiance, McGaw Park, IL). Each slide contained two brain sections from the same rat. The slides were stored at -80°C until use.
Blood AChE assay
Blood samples (50 µl) were obtained from the tail vein prior to treatment on every other day during the 3-week treatment period and diluted with an equal volume of ice-cold heparinized (20 units/ml) saline. Total AChE activity was measured using a modified version (Nostrandt et al., 1993) of traditional assay described by Ellman et al. (1961) . Blood samples were diluted in cold 20 mM Na 2 PO 4 buffer (pH 8.0) and incubated with 3 mM 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) in 0.1 M Na 2 PO 4 buffer (pH 7.0) containing 1.5 mg/ml NaHCO 3 . Incubations were allowed to proceed at room temperature in 96 well plates for 10 min. Then, acetylthiocholine iodide (10 mM in 0.1 Na 2 PO 4 buffer, pH 8.0) was added to each well, and absorbance at 405 nm was measured continuously for 30 min. AChE activity was measured by following the increase of yellow color produced from the reactions between thiocholine and dithiobisnitrobenzoate ion. A standard curve was constructed using glutathione as a source of sulfhydryl groups. AChE activity was expressed as nanomoles of acetylthiocholine iodide hydrolyzed per minute after normalization to blood hemoglobin content. The hemoglobin concentration was determined as described by van Kampen and Zijlstra (1983) . Briefly, 50 µl of diluted blood sample was incubated with 200 µl reagent (200 mg K 3 Fe(CN) 6 , 50 mg KCN, 140 mg KH 2 PO 4 in 1L water), and the absorbance was measured immediately at 550 nm.
AChE histochemistry in the brain
AChE histochemistry was carried out according to the method described previously (Ma et al., 2001) . Prior to incubation, brain slides were brought to room temperature and blown dried under a stream of air for 45 min. The air-dried slices were then incubated in a 50 mM acetate buffer (pH 5.0) containing 2 mM acetylthiocholine iodide (substrate), 2 mM copper sulfate and 10 mM glycine. Reactions were preceded at 37°C for 1 hr. After incubation, the brain sections were passed through five changes in 50 mM acetate buffer (pH 5.0) and then incubated in 1.25% sodium sulfide solution in distilled water (pH 6.5, freshly made) for 1 min at room temperature. After five further changes in 50 mM acetate buffer (pH 5.0), brain sections were transferred to a 1% silver nitrate solution in distilled water for 1 min, followed by five changes in 50 mM acetate buffer (pH 5.0). Finally, the sections were dipped quickly into cold distilled water and blown dried under air at room temperature.
Autoradiography of ligand binding
Binding assays were performed on adjacent sections from selected levels of each brain. Quantitative binding was performed by method similar to previous reports for [ 3 H]QNB binding (Wamsley et al., 1981) (Gattu et al., 1997 ).
[ 3 H]QNB binding
Brain sections were rehydrated and incubated before labeling for 30 min in 10 mM phosphate-buffered-saline (PBS, pH 7.4) and dried by cool air. Slides were incubated at 25°C for 2 hr with 1 nM [ 3 H]QNB in PBS buffer. At the end of the incubation, the slides were rinsed twice (5 min each) with the same buffer at 4°C and then were rapidly dried under a stream of cold air. Adjacent sections were incubated with 40 µM atropine to determine non-specific binding.
[ 3 H]pirenzepine binding
Slides were incubated in 50 mM Tris-HCl buffer (pH 7.4) and 10 nM [ 3 H]pirenzepine and incubated for 90 min at room temperature, washed in the buffer three times and dried. Nonspecific binding was determined by the addition of 10 µM unlabeled atropine to the incubation buffer.
[ 3 H]AF-DX384 binding
Slides were pre-incubated in Tris-HCl buffer for 15 min before being incubated at room temperature for 90 min in fresh buffer containing 2 nM [ 3 H]AF-DX 384, with or without 10 µM atropine to determine the proportion of specific binding. After this incubation period, slides were transferred through three rinses (4 min each) in Tris-HCl buffer (50 mM, pH7.4) at 4°C, then blown dried.
The dried labeled brain slides were juxtaposed tightly against tritium sensitive film (Kodak Biomax MS film with intensify screen) in light tight X-ray cassette with radioactive standard containing known amounts of radioactivity, stored at −80°C. After different exposure periods, films were developed in Kodak D -19, fixed and dried.
Image analysis
Stained brain sections on slides for AChE assay or imaged films from autoradiography binding were scanned by a digital scanning densitometer (Personal Densitometer, Molecular Dynamics, Sunnyvale, CA). Optical density (OD) was used to indicate AChE staining intensities. Optical density from autoradiograms was converted to binding densities using a regression curve derived from the radioactive standards.
Statistical analysis
Analyses were conducted using Jandel Scientific software SigmaStat, Version 2.03 (SPSS Science Inc., Chicago, IL). Details are described in legends of figures.
RESULTS
General toxic signs and body weight
The patterns of the changes in body weight during the treatment period in both control and MP-treated rats were shown in Fig. 1 . There was no obvious evidence that repeated MP exposures caused significant decreases in body weight gain except on day 7. A slight delay in growth was observed in the first 10 days, after which control and MP-treated rats gained weight steadily in a similar rate. But due to the slower growing in the earlier time, MP-treated rats were lighter than the control rats.
Animals repeatedly exposed to 3 mg/kg MP only showed slight signs of OP poisoning (e.g. tremor, irritating, purposeless chewing and lacrimation). Evidence of the tolerance developed to MP is provided by the transience of toxic signs. These signs, primarily a fine tremor, were observed during the treatment (Fig.  2) . The tremors clearly appeared after the 3 rd injection in MP-treated rats but not in control rats. In MP-treated group, it reached a maximum after the 9 th injection, and declined thereafter. The incidence of tremors was not detected after day 15.
Inhibition of AChE in the whole blood and brain
As shown in Fig.3 , the AChE activity in the blood, which was obtained and measured 24 hr after the injections of MP, decreased after successive injections until the minimal activity (30% of control activity) was reached. Then the blood AChE activity stayed Fig. 1 . Changes in body weights during 3 weeks of repeated injections with vehicle (n = 7) and MP (n = 9, 3 mg/kg/day, s.c.). Data are presented as body weight change (g) to Day 0 (Mean ± SEM). Data were analyzed by Two Way Repeated ANOVA, followed by Student-Newman-Keuls's analysis. * Significant difference in body weight change between control and MP-treated rats (p < 0.05).
Vol. 28 No. 5 at this level throughout the treatment. Representative images of brain AChE histochemical staining in the brain sections from the control and MP-treated rats are shown in Photo 1. Highest intensity of AChE staining was detected in the striatum, followed by thalamus, midbrain and hippocampus of the control rats. A significant inhibition of AChE was found in all brain regions examined following 1 week and 3 weeks of MP treatments. About 54~74% of the AChE activity was inhibited after 1 week of MP injections. The inhibition became more extensive during further treatments. At the end of 3-week treatment, only 13~20 % of AChE activities remained (Table1).
Muscarinic receptor binding density in the brain
Representative autoradiograms of [ 3 H]QNB (a non-selective muscarinic receptor antagonist ) binding in brain sections from control and MP-treated rats are shown in Photo 2. [ 3 H]QNB binding site was heterogeneously distributed in the brain. The most QNB binding sites were found in hippocampus, striatum and cerebral cortex, with relatively lower levels in the thalamus and midbrain. [ 3 H]QNB binding was significantly reduced in all five brain regions examined after 3 weeks of MP treatments. The greatest reduction was found in the striatum. The binding was reduced to 70% of the control level. However, only a reduction in muscarinic receptor binding level was detected in the striatum after the first week of treatments (Fig. 4A) .
Further 3 H]pirenzepine binding was decreased by 21, 9 and 22% in the frontal cortex, hippocampus and striatum, respectively (Fig. 4B ). As showed in Fig. 4C 3 H]AF-DX384 binding started to reduce in the first week at selected brain regions, the frontal cortex, striatum and thalamus. At the end of 3 weeks of MP treatments, it was decreased by 22, 11, 38, 6 and 10% in the frontal cortex, hippocampus, striatum, thalamus and midbrain, respectively.
DISCUSSION
Organophosphate-induced alterations in muscarinic receptor activity in the central nervous system have been well documented. Several pervious in vivo studies reported a reduction in the number of muscarinic receptors in certain brain areas as a result of chronic exposure to various OPs (Schiller, 1979; Costa et al., 1982; Russell and Overstreet, 1987) .
Recent study in this laboratory indicated the development of tolerance following a subacute MP treatments in Sprague-Dawley rats in terms of timecourse of symptoms, constant AChE inhibition, and down-regulation of mAChRs. The down-regulation was present in the first week in selected regions and became more extensive with the longer duration of treatments.
The AChE activity in the blood, which was obtained from rats 24 hr after the previous MP injection, decreased with successive injections until the minimal activity (30% of control activity) was reached. The data on AChE inhibition found in the present study are in good agreement with those reported in the literature (van Dongen and Wolthuis, 1989) . Based on the findings reported by van Dongen and Wolthuis (1989), AChE activities in the blood and tissue obtained 24 hr after previous injection are higher than the activities of those 1 hr after the injection. This indicates that some new enzymes have been synthesized during the 23-hr period. So, the real enzyme activity right after each injection could be even lower. As shown in Photo 1, AChE is distributed heterogeneously throughout the brain, and the relative regional preponderance is in the striatum and thalamus. This study also demonstrated that repeated MP exposures inhibit AChE in a similar degree in different brain regions.
The distribution of muscarinic receptors in the Fig. 3 . Blood cholinesterase activity during 3 weeks of repeated MP injections. The blood acetylcholinesterase activity was measured as described in MATERIALS AND METHODS. Data are presented as percentage of control value measured at the same day from the control rats. Each symbol represents the Mean ± SEM (n = 9).
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brain (Yamamura and Snyder, 1974; Kuhar and Yamamura, 1975) , including M 1 -and M 2 -pharmacological subtypes (Mash and Potter, 1986; Giraldo et al., 1987; Regenold et al., 1987) , has been extensively studied by ligand binding. The relation of muscarinic receptor binding sites, defined by various ligands, to the genetically distinct receptor proteins is complicated and uncertain (Dorje et al., 1991 + + ity to multiple subtypes (m 2 and m 4 ). Therefore, the binding sites localized using these or other selective compounds probably correspond to a mixture of multiple receptor proteins, and the exact composition would be expected to vary depending on the tissue in which the receptor expressed and the binding conditions used for the assay. M 1 receptors are the most abundant pharmacological subtype in the cerebral cortex and striatum (Mash and Potter, 1986 ). They include m 1 and m 4 proteins, although m 1 is relatively higher in the cortex and m 4 is relatively higher in the striatum (Dorje et al., 1991) . Dorje et al. (1991) 3 H]AF-DX384 binding started to decrease after the first week in the frontal cortex and striatum and significantly reduced to 60% of the control level in the striatum after 3 weeks of MP treatments. Our finding agrees with a previous report (Frey et al., 1989) which observed significant reductions in both M 1 and M 2 receptor subtypes in brain areas with high levels of presynaptic cholinergic inputs (i.e., cortex, hippocampus and striatum) immediately following a 10-day treatment with DFP. The cholinergic neural regulation of the brain can be determined by the density of innervation, cholinergic nervous activity and the distribution or sensitivity of cholinergic receptors. Previous study showed a significant regional variation on the density of cholinergic innervation to the brain and also in the level, synthesis or turnover rate of endogenous ACh (Stavinoha et al., 1974) . In addition, Stavinoha et al. (1976) measured the accumulation of ACh in rat brain regions after administration of dichlorvos and demonstrated that the striatum had the highest rate of accumulation of ACh followed by cerebral cortex and hippocampus, and the cerebellum had the lowest. The larger accumulation of neurotransmitter, ACh, may explain the greater downregulation of receptor in this region. The evidence that OPs may interact directly with membrane receptor independently of their inhibitory effect on AChE suggest that receptor down-regulation due to chronically elevated ACh levels may not adequately explain the reduction in muscarinic receptor binding sites upon OPs exposures (Volpe et al., 1985; Katz and Marquis, 1989) . Volpe et al. (1985) reported that OPs at concentration below those needed to inhibit AChE, had direct effect on muscarinic receptor binding in isolated membrane from bovine caudate nucleus. OPs decreased the total number of [ 3 H]QNB binding sites and exhibited no effect on the affinity of central muscarinic receptors. Katz and Marquis (1989) further indicated that the subpopulation of muscarinic receptors which was found to be sensitive to modulation of paraoxon consist of the M 2 and M 3 binding site. The high level of m 4 and m 2 protein in the striatum (Levey et al., 1991) and similar affinity to M 2 -selective ligands (Dorje et al., 1991) is also a possible explanation of the dramatic response in M 2 binding in striatum.
In summary, the present study showed that muscarinic receptors, both M 1 and M 2 , underwent comparable modulation in response to repeated MP exposures. But there are differences in terms of time course and extent among brain regions. This probably due to differential sensitivity of each subtype to MP and differential distribution of receptor subtype proteins in brain regions. To clearly understand the role of each subtype, using antibodies specific to receptor subtypes and molecular probes to measure specific proteins and mRNAs could be the solutions. To determine whether this down-regulation of receptor is related to the impairment of physiological functions, further behavioral studies are also needed.
